First-in-human / early research/company pr/Sana Biotechnology

Hypoimmune islet cells (UP421 / SC451)

Reported early human data suggested engineered cells could survive without immunosuppression. This is very early signal and must be read as preliminary, not proof.

How it works

Islet cells are genetically engineered to evade the immune system (a 'hypoimmune' design), aiming to transplant them without immune-suppressing drugs. SC451 extends the idea to stem cell-derived islets.

Approach
Gene-engineered immune-evasive islet cells
Immunosuppression
Designed to avoid immunosuppression

Live trial status

No registered clinical trial is tracked for this program yet (it may be preclinical or early). See the official program links for the latest.

These are research programs pursuing a functional cure or disease modification for type 1 diabetes. None is a confirmed, broadly available cure. Trial status is informational, not medical advice, and not a recruiting offer. Verify eligibility and details with the official trial record and a clinician.

Family-tested T1D gear

Some links below are affiliate links. If you buy through them, Type1Cure may earn a small commission at no extra cost to you. Affiliate relationships never affect our research coverage, evidence labels, rankings, or safety alerts.